How to buy Aerie Pharmaceuticals stock (AERI)

Aerie Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Aerie Pharmaceuticals shares (AERI) are listed on the NASDAQ and all prices are listed in US Dollars. Aerie Pharmaceuticals employs 376 staff and has a trailing 12-month revenue of around $213.9 million.

Our top picks for where to buy Aerie Pharmaceuticals stock

Buy Aerie Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aerie Pharmaceuticals stock price (NASDAQ: AERI)

Use our graph to track the performance of AERI stocks over time.

Aerie Pharmaceuticals shares at a glance

• Key figures

Information last updated 2023-02-26.

52-week range	$0.00 - $0.00
50-day moving average more info button	$15.19
200-day moving average more info button	$10.24
Wall St. target price	$15.35
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.47

Is it a good time to buy Aerie Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerie Pharmaceuticals financials

Revenue TTM	$213.9 million
Gross profit TTM	$167.3 million
Return on assets TTM	-4.59%
Return on equity TTM	-2255.01%
Profit margin	-17.09%
Book value	$-3.32
Market Capitalization more info button	$753.6 million

TTM: trailing 12 months

Aerie Pharmaceuticals share dividends

We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months.

Aerie Pharmaceuticals share price volatility

Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is -0.062. This would suggest that Aerie Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aerie Pharmaceuticals has bucked the trend.

Aerie Pharmaceuticals overview

Aerie Pharmaceuticals, Inc. , a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Frequently asked questions

null
What percentage of Aerie Pharmaceuticals is owned by insiders or institutions?
Currently 1.791% of Aerie Pharmaceuticals shares are held by insiders and 102.995% by institutions. How many people work for Aerie Pharmaceuticals?
Latest data suggests 376 work at Aerie Pharmaceuticals. When does the fiscal year end for Aerie Pharmaceuticals?
Aerie Pharmaceuticals's fiscal year ends in December. Where is Aerie Pharmaceuticals based?
Aerie Pharmaceuticals's address is: 4301 Emperor Boulevard, Durham, NC, United States, 27703 What is Aerie Pharmaceuticals's ISIN number?
Aerie Pharmaceuticals's international securities identification number is: US00771V1089 What is Aerie Pharmaceuticals's CUSIP number?
Aerie Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00771V108